#samsungbiologics — Public Fediverse posts

GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio

For media and investors only Issued: London, UK and Songdo, S. KOREA GlaxoSmithKline and Samsung Biologics have entered…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/200691/

Samsung Biologics beats estimates, raises annual sales growth guidance to 20%

Q3 sales 1.49 trillion won, operating profit 640.1 billion won — above analyst forecasts Annual sales target raised…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/200625/

Samsung Biologics Q3 net income down over 20%

Samsung Biologics’ plant 4 in Incheon’s Songdo / Courtesy of Samsung Biologics Samsung Biologics, the biotech arm of…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/200601/

Incheon City Proclaims ‘Global Innovative Drug Hub’… Launches Multilateral Cooperation with Lilly and Samsung Biologics

Restructuring Industry from Contract Manufacturing to “Innovative Drug R&D”Incheon to Host the World’s Seventh “Lilly Gateway Labs”Mayor Park…
#EuropeSays #Korea #KR #SamsungBiologics #Economic #Issue #news #Newspaper #politics #Samsung #Society #SouthKorea #TheAsiaBusinessDaily
https://www.europesays.com/korea/200553/

Samsung Biologics wins court injunction covering all nine manufacturing stages

News Samsung Biologics wins court injunction covering all nine manufacturing stages The ruling significantly expands the scope of…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/200505/

South Korea’s Hanmi Pharmaceutical Launches Obesity Drug EPPE on Oct. 29 at approximately $98 per 4-Week Supply — BigGo Finance

South Korea’s Hanmi Pharmaceutical will begin prescribing its domestically developed obesity treatment EPPE (active ingredient efpeglenatide) at some…
#EuropeSays #Korea #KR #Celltrion #EPPE #HanmiPharmaceutical #Kaigene #KG013 #Korean #Mounjaro #SamsungBiologics #SouthKorea'sMinistryofFoodandDrugSafety #Wegovy
https://www.europesays.com/korea/199637/

Samsung Biologics surges around 8% on easing strike concerns and earnings optimism [Stock NOW]

A view of Samsung Biologics’ Plant 4. Provided by Samsung Biologics. [Financial News] Samsung Biologics is surging around…
#EuropeSays #Korea #KR #SamsungBiologics #economy #financialnews #fnnews #news #Samsung
https://www.europesays.com/korea/199365/

Samsung Securities maintained its “buy” investment opinion and target stock price of 1.8 million won..

사진 확대 Samsung Biologics Plant 4. Samsung Securities maintained its “buy” investment opinion and target stock price of…
#EuropeSays #Korea #KR #SamsungBiologics #InvestmentOpinion #operatingprofit #Samsung #SamsungSecurities #samsung-bio
https://www.europesays.com/korea/199251/

“Jobs at Samsung BioLogics and Samjin Pharm, Too”… Asia Business Daily Recruits for Government-Funded Medical AI and Digital Healthcare Training

– Hands-on training in AI drug development, digital biomarkers, and medical imaging analysis using more than 300,000 medical…
#EuropeSays #Korea #KR #SamsungBiologics #Economic #Issue #news #Newspaper #politics #Samsung #Society #SouthKorea #TheAsiaBusinessDaily
https://www.europesays.com/korea/199215/

Samsung Biologics lifts 2024 sales outlook as Q3 margin dips on US ramp-up

In front of the Samsung Biologics headquarters in Songdo, Incheon. /Courtesy of News1 Samsung Biologics(207940) said in a…
#EuropeSays #Korea #KR #SamsungBiologics #ChosunBiz #Samsung #technology
https://www.europesays.com/korea/198635/

Samsung Biologics raises 2026 growth outlook as quarterly revenue reaches KRW 1.49 trillion

Samsung Biologics raises 2026 growth outlook as quarterly revenue reaches KRW 1.49 trillion October 22, 2026 | Thursday…
#EuropeSays #Korea #KR #SamsungBiologics #biologics #Biomanufacturing #CDMO #peptidemanufacturing #Plant5 #PolyPeptide #quarterlyresults #rightsoffering #rockville #Samsung
https://www.europesays.com/korea/198599/

Samsung Biologics Labor and Management to Meet on Oct. 28, Discuss Resuming Negotiations

Positions remain far apart on wages and performance bonuses Samsung Biologics’ labor and management are set to hold…
#EuropeSays #Korea #KR #SamsungBiologics #Economic #Issue #news #Newspaper #politics #Samsung #Society #SouthKorea #TheAsiaBusinessDaily
https://www.europesays.com/korea/198022/

Samsung Biologics Reports Third Quarter 2026 Financial Results

Recorded Q3’26 revenue of KRW 1,490 billion and operating profit of KRW 640 billionPlant 5 ramp-up and U.S.…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197974/

Samsung Biologics posts earnings surprise despite strike and currency headwinds

Samsung Biologics Quarterly Performance Trends / Graphic by Yoon Sun-jung Despite the burden of its first-ever strike and…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197796/

Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth

Operating profit reaches KRW 640 billion as Plant 5 ramp-up and US operations strengthen performance, prompting the CDMO…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung #SamsungBiologicsReportsKRW1.49TrillionQ3RevenueasGlobalManufacturingExpansionDrivesGrowth
https://www.europesays.com/korea/197756/

Samsung Biologics Q3 net income down over 20%

Samsung Biologics’ plant 4 in Incheon’s Songdo / Courtesy of Samsung Biologics Samsung Biologics, the biotech arm of…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197716/

Samsung Biologics showcases end-to-end CDMO capabilities at World ADC San Diego

Company secures solo booth for third consecutive year at world’s top ADC conference, highlighting integrated CRO, CDO and…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197580/

Samsung Biologics posts record quarterly sales, raises annual growth guidance to 20%

Q3 operating profit reaches 640.1 billion won on full-capacity operations and Rockville acquisition Cumulative orders surpass $22 billion;…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197536/

Samsung Biologics Beats Estimates on Rockville Plant, Plant 5 Ramp-Up

A view of the Samsung Biologics building. Photo courtesy of Samsung Biologics Samsung Biologics (207940) posted third-quarter results…
#EuropeSays #Korea #KR #SamsungBiologics #CDMO #KiwoomSecurities #Plant5 #PolyPeptide #Rockvilleplant #Samsung #third-quarterearnings
https://www.europesays.com/korea/197446/

“Rockville plant offsets impact of strike”; Samsung Biologics target price: 1.9 million won

A view of the biopharmaceutical production facility in Rockville, Maryland, U.S., secured by Samsung Biologics. Photo provided by…
#EuropeSays #Korea #KR #SamsungBiologics #economy #financialnews #fnnews #news #Samsung
https://www.europesays.com/korea/197398/

Kiwoom Securities keeps Samsung Biologics at 2 million won on stronger outlook

A view of Samsung Biologics headquarters./Courtesy of Samsung Biologics Kiwoom Securities said on the 22nd that Samsung Biologics(207940)…
#EuropeSays #Korea #KR #SamsungBiologics #KOSDAQ #KOSPI #Samsung #securities
https://www.europesays.com/korea/197360/

Samsung Bio union expands lunch rallies, presses Korea talks in good faith

The Samsung Biologics labor union says it has been holding lunchtime rallies at the company’s biopark since the…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197322/

Samsung Biologics Reports Third Quarter 2026 Financial Results

Recorded Q3’26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197282/

Samsung Biologics lifts 2024 sales outlook as Q3 margin dips on US ramp-up

In front of the Samsung Biologics headquarters in Songdo, Incheon. /Courtesy of News1 Samsung Biologics(207940) said in a…
#EuropeSays #Korea #KR #SamsungBiologics #ChosunBiz #Samsung #technology
https://www.europesays.com/korea/197242/

Samsung Biologics confident of 20% annual revenue growth despite strike and weak won

Samsung Biologics quarterly performance trends / Graphic by Yoon Sun-jung Despite the burden of its first-ever strike and…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197192/

Samsung Biologics Q3 Revenue Up 19%… Raises Full-Year Guidance

Revenue of KRW 1.493 trillion; operating profit of KRW 640.1 billion“Plants 1 through 4 at full capacity, with…
#EuropeSays #Korea #KR #SamsungBiologics #Economic #Issue #news #Newspaper #politics #Samsung #Society #SouthKorea #TheAsiaBusinessDaily
https://www.europesays.com/korea/197144/

Samsung Biologics Q3 sales jump 19% on full plant run

Samsung Biologics’ Plant 4 in Songdo/ Courtesy of Samsung Biologics
 

SEOUL, October 21 (AJP)…
#EuropeSays #Korea #KR #SamsungBiologics #Samsung
https://www.europesays.com/korea/197040/